ArticleTranslational lung cancer research2026
Pulmonary ground-glass opacity associated with cystic airspace: clinicopathological features and aggressiveness.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary ground-glass opacity (GGO) is often considered to have inert biological behavior. However, whether the clinicopathological features and aggressiveness of GGO associated with cystic airspace (GGO-A) differ from GGO associated without cystic airspace (GGO-nA) remains unknown. This study aimed to compare the clinicopathological features and aggressiveness of GGO-A with GGO-nA. Methods: This retrospective study included patients with GGOs [lesion size: 0.5-2.0 cm, consolidation-to-tumor ratio (CTR) ≤50%] from 2017 to 2021. Patients were divided into GGO-As and GGO-nAs. Chi-squared, Mann-Whitney test, Kaplan-Meier analyses and Logistic regression were utilized for data analysis. Results: A total of 818 patients (266 with GGO-As and 552 with GGO-nAs) were enrolled. Compared to patients with GGO-nAs, patients with GGO-As had distinct clinical features: male [odds ratio (OR) =5.588, P<0.001], without family history of cancer (OR =5.121, P<0.001), with emphysema pulmonum (OR =3.228, P=0.003) and with pulmonary bullae (OR =2.634, P<0.001). Compared to GGO-nAs, GGO-As had more invasive adenocarcinomas (IAs) (75.8% Conclusions: GGO-A showed higher aggressiveness compared to GGO-nA, with more invasive histological subtypes, a higher frequency of KRAS mutations, and faster radiological progression. These findings suggested more proactive surveillance and potentially aggressive clinical management for GGO-As.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.